A national registry for pregnant women taking atypical antipsychotics, including one named in Risperdal lawsuit filings, has been created to monitor the risk for congenetic malformations and other side effects in their unborn children, according to Clinical Psychiatry News.

The registry was created by the clinical director of the Women’s Mental Health Center at Massachusetts General Hospital after data obtained over a 6-year period revealed a 2.5-fold increase in the number of antipsychotic drug scripts written to women 60 days or fewer before giving birth. The study was published last year and involved 585,615 deliveries between 2001 and 2007.  Among other things, the study found that 0.72 percent of women received a medication similar to Risperdal, compared to 0.09 percent who received a typical antipsychotic, to treat depression, schizophrenia and bipolar disorder, among other conditions.

Pregnancy Registry Tracks Outcomes of Risperdal, other Drugs

In 2011, a national registry was created at Massachusetts General Hospital to track outcomes of pregnant women taking atypical antipsychotics. More than 400 individuals have since been enrolled in the National Pregnancy Registry, which recently showed the rate of major malformations in children born to mothers using the medications to be two times greater than those in a control group. There was little difference in those prescribed first-generation atypical antipsychotics compared to second-generation drug versions, research found.

“Our registry is carefully, prospectively done,” said its creator, who later stressed the importance of collecting detailed data that relates to atypical pregnancy. “It’s all done by phone, with two calls during pregnancy and one post-partum.”

As a whole, the number of prescriptions written for Risperdal and other drugs is on the rise in demographics across the board. This Johnson & Johnson medication in particular is currently approved for adults and adolescents with bipolar disorder and schizophrenia, as well as in the treatment for irritability in children with autism. It is also frequently prescribed off-label to treat symptoms associated with ADHD, and in elderly patients with dementia. Over the past few years, the number of lawsuits alleging Risperdal gynecomastia and other complications has also grown. There are now more than 350 claims against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, in a consolidated litigation established in the Philadelphia Court of Common Pleas in Pennsylvania. Plaintiffs in these cases accuse the company of concealing safety information about its product from the general public.

Filing a Risperdal Lawsuit

Call our Firm to learn more about Risperdal lawsuits that have already been filed, and about the process of filing a claim of your own. Our attorneys can be reached directly at (877) 779-1414.

Published May 5, 2014 by